Farmaforum Partnering Day 2025

18 Sept 2025 | Madrid, Spain

Register
Register
Register

InvestmentUpdated on 15 July 2025

Advanced Therapys for liver diseases

Alejandro Exposito

COO at Servatrix

Madrid, Spain

About

Liver fibrosis in the form of MASH is the most common liver disorder worldwide, will affect approximately 25% of world´s population (1 in 4)
TAM of 27 B
Currently, only one drug has received provisional FDA approval for MASH after 1 year of clinical trial. with some concerns: results after completion of the 5-year clinical trial / optimization of dosing and timing / long term safety / very expensive / not covered by Health Systems for a chronic treatment
But oru approach in totally new, Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that regulates the expression of multiple defensive genes.NRF2 makes heterodimers with small MAFs and activates genes containing the Antioxidant response Element (ARE).

Similar opportunities

  • Service

    R&D and Clinical Genomic Services

    • Development
    • Cosmetic industry
    • Laboratory industry
    • Pharmaceutical industry

    Marc del Pino

    Southern Europe Sales Manager at GENEWIZ

    Barcelona, Spain

  • Service

    R&D of Generyc & Hybryd Drugs

    • Consulting
    • Development
    • Health innovation
    • Laboratory industry
    • Pharmaceutical industry

    Kseniya Tymko

    Business Development Director at Pharmbiotest Poland Ltd

    Grudziadz, Poland

  • Service

    Clinical Trial Supply & Logistics Services

    • Development
    • Manufacturing
    • Pharmaceutical industry

    Marc Brehme

    Founder & Managing Director at M-B-V-C

    Vienna, Austria